Friday, 16 October 2026European Markets

ITESOFT Stock Went Down By Over 10% So Far Today

Loading stream...

(vianews) - shares of itesoft (cac 40: ite.pa) dropped by a staggering 10.11% to €3.38 at 14:55 est on tuesday, after four sequential sessions in a row of losses. cac 40 is falling 0.2% to €7,169.89, following the last session's upward trend. this seems, so far, a somewhat bearish trend trading session today.

about itesoft

itesoft s.a., a software company, provides secure capture and process automation solutions in france and internationally. the company's solutions include itesoft capture as a service, a solution for capturing information with digitization and the acceleration of exchanges; itesoft capture as a service for invoices, provides cloud-based invoice data extraction, and automation service based on a single and multi-tenant core technology. it also offers itesoft fraud detection saas, a solution that identifies suspicious documents. in addition, the company provides itesoft freemind, a solution for enterprises to process all document flows in various formats, such as paper, barcode, fax, email, and manuscript; and itesoft freemind for invoices, a solution for capturing and extracting supplier invoices. further, it offers itesoft balance, a solution that handles reconciliation, accounting integration in sap, and oracle certified erp and generic erp modules; and itesoft analytics that supervises entire process invoices from reception to payments. it serves customers in banking, insurance, commerce, industry, public sector, social organizations, etc. itesoft s.a. was incorporated in 1984 and is headquartered in aimargues, france. itesoft s.a. is a subsidiary of cdml sas.

earnings per share

as for profitability, itesoft has a trailing twelve months eps of €-0.23.

volume

today's last reported volume for itesoft is 7646 which is 4864.93% above its average volume of 154.

more news about itesoft (ite.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com